cytoTIL therapy

Md Anderson And Obsidian Therapeutics Announce Strategic Collaboration To Accelerate Advancement Of Novel Engineered Tumor Infiltrating Lymphocyte Therapy (Cytotil) For Solid Tumors

The University of Texas MD Anderson Cancer Center and Obsidian Therapeutics, Inc. today announced a multi-year strategic collaboration designed to expedite the research and development of novel engineered tumor infiltrating lymphocytes (TILs) for the treatment of solid tumors. The agreement pairs Obsidian and its novel cytoDRiVE™ technology platform with MD Anderson’s extensive experience and state-of-the-art capabilities in TIL cell therapy, led by the Biologics Development platform, within the Therapeutics Discovery division. The collaboration is focused on developing TIL armored with regulated […]